Next Article in Journal
Decoding Biosynthetic Pathways in Plants by Pulse-Chase Strategies Using 13CO2 as a Universal Tracer
Previous Article in Journal
Complex Mixture Analysis of Organic Compounds in Yogurt by NMR Spectroscopy
Article Menu

Export Article

Open AccessReview
Metabolites 2016, 6(3), 20; doi:10.3390/metabo6030020

Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health

BERG, 500 Old Connecticut Path, Bldg. B, Framingham, MA 01701, USA
Academic Editor: Peter Meikle
Received: 19 April 2016 / Revised: 6 June 2016 / Accepted: 1 July 2016 / Published: 8 July 2016
View Full-Text   |   Download PDF [997 KB, uploaded 8 July 2016]   |  

Abstract

Metabolomics has emerged as an essential tool for studying metabolic processes, stratification of patients, as well as illuminating the fundamental metabolic alterations in disease onset, progression, or response to therapeutic intervention. Metabolomics materialized within the pharmaceutical industry as a standalone assay in toxicology and disease pathology and eventually evolved towards aiding in drug discovery and pre-clinical studies via supporting pharmacokinetic and pharmacodynamic characterization of a drug or a candidate. Recent progress in the field is illustrated by coining of the new term—Pharmacometabolomics. Integration of data from metabolomics with large-scale omics along with clinical, molecular, environmental and behavioral analysis has demonstrated the enhanced utility of deconstructing the complexity of health, disease, and pharmaceutical intervention(s), which further highlight it as an essential component of systems medicine. This review presents the current state and trend of metabolomics applications in pharmaceutical development, and highlights the importance and potential of clinical metabolomics as an essential part of multi-omics protocols that are directed towards shaping precision medicine and population health. View Full-Text
Keywords: metabolomics; mass spectrometry; biomarkers; pharmaceutical; drug; patients metabolomics; mass spectrometry; biomarkers; pharmaceutical; drug; patients
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Tolstikov, V. Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health. Metabolites 2016, 6, 20.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Metabolites EISSN 2218-1989 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top